斯健康报告了2026年第一季度的收入为252亿美元,增长12%. Bausch Health reported Q1 2026 revenue of $2.52 billion, up 12%.

斯健康报告了2026年第一季度的收入为252亿美元,其 Salix 和 Solta 分段带来的增长率为12%. Bausch Health reported Q1 2026 revenue of $2.52 billion, a 12% increase driven by its Salix and Solta segments. 调整后每股收益增长32%,达到0.78美元,而调整之后的EBITDA则达到了8.37亿美元. Adjusted earnings per share rose 32% to $0.78, while adjusted EBITDA reached $837 million. 尽管公司受到大幅度的值指数,但该公司仍保持了全年预期. The company maintained its full-year guidance despite a significant goodwill impairment charge.